Literature DB >> 10475975

In vitro correlate of immunity in an animal model of inhalational anthrax

.   

Abstract

The incidence of anthrax in humans is extremely low. Human vaccine efficacy studies for inhalational anthrax cannot be conducted. The identification of a correlate of protection that predicts vaccine efficacy is crucial for determining the immune status of immunized humans. This surrogate marker of immunity can only be established by using an appropriate animal model. Numerous studies showed that protective antigen (PA) is the principle protective antigen in naturally- or vaccine-induced immunity. However, attempts to correlate the quantity of anti-PA antibodies with protective immunity in the guinea pig model for anthrax and various vaccine formulations have failed. In these studies, we used the licensed anthrax vaccine adsorbed (AVA) in rabbits. Groups of New Zealand white rabbits, 10 or 20 per group, were immunized intramuscularly (two doses, 4 weeks apart) with varying doses of AVA, ranging from a human dose to 1:256 dilution in sterile phosphate-buffered saline (PBS). Control rabbits received PBS/Alhydrogel according to the same schedule. Each rabbit was bled 2 weeks after the second dose, and antibody levels to PA measured by both the quantitative anti-PA IgG ELISA and the toxin-neutralizing antibody (TNA) assay. Rabbits were aerosol-challenged 10 weeks from day 0 with a lethal dose of Ames spores. All the rabbits that received the undiluted and 1:4 dilution of vaccine survived, whereas those receiving the higher dilutions of vaccine (1:16, 1:64 and 1:256) had deaths in their groups. All the controls died. Rabbit survival was compared with the antibody response. Statistical models were used to test for significance of the peak antibody responses to predict survival. Results showed that both the amount of anti-PA IgG and TNA titres present in the sera at the time of the peak antibody response were significant (P < 0.0001) predictors of survival. These results demonstrate that the humoral immune response to AVA can predict protection in the rabbit model of inhalational anthrax.

Entities:  

Year:  1999        PMID: 10475975     DOI: 10.1046/j.1365-2672.1999.00897.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  34 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

3.  Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Authors:  Rebecca A Brady; Anita Verma; Bruce D Meade; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

4.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

6.  Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.

Authors:  Jon Oscherwitz; Conrad P Quinn; Kemp B Cease
Journal:  Vaccine       Date:  2015-03-26       Impact factor: 3.641

7.  Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Authors:  Qin Li; Kristina K Peachman; Laurie Sower; Stephen H Leppla; Sathish B Shivachandra; Gary R Matyas; Johnny W Peterson; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Open Vaccine J       Date:  2009

8.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

Review 9.  Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.

Authors:  Charles E Binkley; Sandro Cinti; Diane M Simeone; Lisa M Colletti
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

10.  Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Authors:  James E Galen; Magaly Chinchilla; Marcela F Pasetti; Jin Yuan Wang; Licheng Zhao; Ivonne Arciniega-Martinez; David J Silverman; Myron M Levine
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.